In a retrospective cohort study that included patients with T2D and cirrhosis, Simon et al. found a lower rate of decompensation events (i.e., ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, or esophageal variceal hemorrhage) among GLP-1 RA users compared to patients receiving other glucose-lowering agents, such as sulfonylureas [84]. Here, GLP1R is linked to hepatorenal syndrome.